Cognitact

Blood-based biomarker panels for early detection of Alzheimer’s disease

What is the Challenge?

Alzheimer’s disease (AD) is the most prevalent form of dementia, affecting over 50 million people worldwide. With numbers expected to triple by 2050, AD imposes a severe health and economic burden, costing over $1.3 trillion annually. Current diagnostic methods, including cognitive tests, brain imaging, and CSF tests, are either subjective, expensive, or invasive, and often identify AD too late for effective intervention. The lack of accessible, early detection tools leaves millions of patients undiagnosed during the critical early stages when treatments like Leqembi could slow disease progression.

What is the Solution?

Cognitact has developed a solution called PlasmarkAD®, an innovative blood-based biomarker test that accurately detects Alzheimer’s disease and mild cognitive impairment (MCI) in its earliest stages. Utilizing a proprietary machine-learning algorithm and a panel of 21 blood proteins linked to AD-related pathologies and biological processes, their solution provides an objective, minimally invasive, and accessible diagnostic solution. This groundbreaking test generates an AD risk score and analyzes biological pathways such as inflammation and neurodegeneration, empowering clinicians with critical insights to guide patient care.

Cognitact’s solution not only simplifies early AD diagnosis but also aligns with the growing demand for scalable, patient-friendly diagnostics. Since its public launch in Hong Kong in July 2023, the test has been made available in private hospitals, clinics, and to individual customers, gaining significant interest from clinicians and the elderly community. By enabling early detection and intervention, Cognitact is transforming the future of cognitive health and improving patient outcomes worldwide.

Latest